Research programme: cardiac ion channel modulators - AnaBios/Sanofi

Drug Profile

Research programme: cardiac ion channel modulators - AnaBios/Sanofi

Latest Information Update: 16 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Sanofi
  • Developer AnaBios Corporation; Sanofi
  • Class Antiarrhythmics
  • Mechanism of Action Ion channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Atrial fibrillation

Most Recent Events

  • 08 Feb 2018 AnaBios Corporation acquires development and commercialisation rights to an undisclosed family of Atrial fibrillation compounds from Sanofi
  • 08 Feb 2018 Preclinical trials in Atrial fibrillation in USA (unspecified route) (9233193; AnaBios Corporation website, February 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top